Abstract:Circulation Research, Ahead of Print. BACKGROUND:Acute ischemic stroke triggers endothelial activation that disrupts vascular integrity and increases hemorrhagic transformation leading to worsened stroke outcomes. rt-PA (recombinant tissue-type plasminogen activator) is an effective treatment; however, its use is limited due to a restricted time window and hemorrhagic transformation risk, which in part may involve activation of MMPs (matrix metalloproteinases) mediated through LOX-1 (lectin-like oxLDL [oxidized low-density lipoprotein] receptor 1). This study's overall aim was to evaluate the therapeutic potential of novel MMP-9 (matrix metalloproteinase 9) and LOX-1 inhibitors in combination with rt-PA to improve stroke outcomes.METHODS:A rat thromboembolic stroke model was utilized to investigate the impact of rt-PA delivered 4 hours poststroke onset as well as selective LOX-1 (BI-0115) and MMP-9 (JNJ0966) inhibitors given before rt-PA administration. Infarct size, perfusion, and hemorrhagic transformation were evaluated by 9.4-T magnetic resonance imaging, vascular and parenchymal MMP-9 activity via zymography, and neurological function was assessed using sensorimotor functioning testing. Human brain microvascular endothelial cells were exposed to hypoxia plus glucose deprivation/reperfusion (hypoxia plus glucose deprivation 3 hours/R 24 hours) and treated with ±rt-PA, ±MMP-9, and LOX-1 inhibitors. Barrier function was assessed via transendothelial electrical resistance, MMP-9 activity was determined with zymography, and LOX-1 and barrier gene expression/levels were measured using qRT-PCR and Western blot.RESULTS:Stroke and subsequent rt-PA treatment increased edema, hemorrhage, MMP-9 activity, LOX-1 expression, and worsened neurological outcomes. LOX-1 inhibition improved neurological function, reduced edema, and improved endothelial barrier integrity. Elevated MMP-9 activity correlated with increased edema, infarct volume, and decreased neurological function. MMP-9 inhibition reduced MMP-9 activity and LOX-1 expression. In human brain microvascular endothelial cells, LOX-1/MMP-9 inhibition differentially attenuated MMP-9 levels, inflammation, and activation following hypoxia plus glucose deprivation/R.CONCLUSIONS:Our findings indicate that MMP-9 and LOX-1 inhibition attenuates negative aspects of ischemic stroke with an rt-PA therapy, thus resulting in improved neurological function. While no synergistic effect was observed with simultaneous LOX-1 and MMP-9 inhibition, a distinct interaction is evident.

Selective inhibition of brain endothelial Rho-kinase-2 provides optimal protection of an in vitro blood-brain barrier from tissue-type plasminogen activator and plasmin

Phosphodiesterase inhibitor modulation of brain microvascular endothelial cell barrier properties.

Tissue plasminogen activator expression and barrier properties of human brain microvascular endothelial cells.

The novel ROCK2 selective inhibitor NRL-1049 preserves the blood-brain barrier after acute injury

Rho-Kinase Inhibitor, Fasudil, Prevents Neuronal Apoptosis Via the Akt Activation and PTEN Inactivation in the Ischemic Penumbra of Rat Brain

Rho-kinase Inhibitor Prevents Acute Injury Against Transient Focal Cerebral Ischemia by Enhancing the Expression and Function of GABA Receptors in Rats.

NLRP3 Inhibition Reduces rt-PA Induced Endothelial Dysfunction under Ischemic Conditions

Beneficial Role of Rosuvastatin in Blood–Brain Barrier Damage Following Experimental Ischemic Stroke

Role of Rho Kinase in Lysophosphatidic Acid-Induced Altering of Blood-Brain Barrier Permeability.

Discovery of a ROCK Inhibitor, FPND, Which Prevents Cerebral Hemorrhage Through Maintaining Vascular Integrity by Interference with VE-cadherin

Apremilast exerts protective effects on stroke outcomes and blood-brain barrier (BBB) dysfunction through regulating Rho-associated protein kinase 2 expression

Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion

Remote ischemic conditioning attenuates blood-brain barrier disruption after recombinant tissue plasminogen activator treatment via reducing PDGF-CC

Delivery Of Anti-Platelet-Endothelial Cell Adhesion Molecule Single-Chain Variable Fragment-Urokinase Fusion Protein To The Cerebral Vasculature Lyses Arterial Clots And Attenuates Postischemic Brain Edema

Prevention of rt-PA induced blood-brain barrier component degradation by the poly(ADP-ribose)polymerase inhibitor PJ34 after ischemic stroke in mice.

Selective blockade of endothelin-B receptors exacerbates ischemic brain damage in the rat

LOX-1 and MMP-9 Inhibition Attenuates the Detrimental Effects of Delayed rt-PA Therapy and Improves Outcomes After Acute Ischemic Stroke

Anfibatide Preserves Blood-Brain Barrier Integrity by Inhibiting TLR4/RhoA/ROCK Pathway After Cerebral Ischemia/Reperfusion Injury in Rat

Computational systematic selectivity of the Fasalog inhibitors between ROCK-I and ROCK-II kinase isoforms in Alzheimer's disease

TGF-β1 Prevents Blood–brain Barrier Damage and Hemorrhagic Transformation after Thrombolysis in Rats

Effects of Rt-Pa Intravenous Thrombolysis on Blood-Brain Barrier Permeability, the Expressions and the Activities of MMP-2 and MMP-9 after Cerebral Ischemia in Rats